Fasciitis as a common lesion of dermatomyositis, demonstrated early after disease onset by en bloc biopsy combined with magnetic resonance imaging

Arthritis Care and Research

Volumn 62, Issue 12, 2010, Pages 3751-3759

  Yoshida, Ken ^a   Kurosaka, Daitaro ^a   Joh, Kensuke ^b   Matsushima, Satoshi ^a   Takahashi, Eigo ^a   Hirai, Kenichiro ^a   Noda, Kentaro ^a   Ukichi, Taro ^a   Furuya, Kazuhiro ^a   Yanagimachi, Maimi ^a   Kingetsu, Isamu ^a   Fukuda, Kunihiko ^a   Yamada, Akio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOSPORIN A; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CELL INFILTRATION; CLINICAL ARTICLE; DERMATOMYOSITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG PULSE THERAPY; FASCIITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFLAMMATION; MALE; MATURITY ONSET DIABETES MELLITUS; MICROVASCULARIZATION; MUSCLE BIOPSY; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SCORING SYSTEM; BIOPSY; CONTROLLED STUDY; FASCIA; INFLAMMATORY INFILTRATE; MICROVASCULATURE; MUSCLE INJURY; PRIORITY JOURNAL;

ADULT; AGED; BIOPSY; DERMATOMYOSITIS; DISEASE PROGRESSION; FASCIITIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 78650050697     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27704     Document Type: Article

References (31)

1. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
2. Mastaglia FL, Ojeda VJ,. Inflammatory myopathies: Part 1. Ann Neurol 1985; 17: 215-27.
3. Whitaker JN,. Inflammatory myopathy: a review of etiologic and pathogenetic factors. Muscle Nerve 1982; 5: 573-92.
4. Carpenter S, Karpati G,. The major inflammatory myopathies of unknown cause. Pathol Annu 1981; 16: 205-37.
5. Whitaker JN, Engel WK,. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972; 286: 333-8.
6. Kissel JT, Mendell JR, Rammohan KW,. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-34.
7. Crowson AN, Magro CM,. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996; 27: 15-9.
8. Dalakas MC,. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
9. Dubowitz V, Sewry CA,. Inflammatory myopathies. In: Muscle biopsy: a practical approach. 3rd ed. Philadelphia: Saunders Elsevier; 2007. p. 519-39.
10. Engel AG, Hohlfeld R,. The polymyositis and dermatomyositis syndromes. In:, Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 2004. p. 1321-66.
11. Crowe WE, Bove KE, Levinson JE, Hilton PK,. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25: 126-39.
12. Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: implications for diagnosis and therapy. Arthritis Rheum 2000; 43: 1866-73.
13. Adams EM, Chow CK, Premkumar A, Plotz PH,. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 1995; 15: 563-74.
14. Krug B, Kugel H, Schulze HJ, Krahe T, Gieseke J, Lackner K,. High-resolution MR imaging of the cutis and subcutis: histological correlation. Acta Radiol 1998; 39: 547-53.
15. Allen E, Schmahmann S, Sauser D, Barkhuizen A,. Fasciitis in amyopathic dermatomyositis. J Clin Rheumatol 2003; 9: 51-3.
16. Tsuruta Y, Ikezoe K, Nakagaki H, Shigeto H, Kawajiri M, Ohyagi Y, et al. A case of dermato-fasciitis: amyopathic dermatomyositis associated with fasciitis. Clin Rheumatol 2004; 23: 160-2.
17. Kaufman LD, Gruber BL, Gerstman DP, Kaell AT,. Preliminary observations on the role of magnetic resonance imaging for polymyositis and dermatomyositis. Ann Rheum Dis 1987; 46: 569-72.
18. Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994; 37: 736-46.
19. Fleckenstein JL, Reimers CD,. Inflammatory myopathies: radiologic evaluation. Radiol Clin North Am 1996; 34: 427-39.
20. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD,. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597-613.
21. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
22. Gherardi RK, Coquet M, Cherin P, Authier FJ, Laforet P, Belec L, et al, Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). Macrophagic myofasciitis: an emerging entity. Lancet 1998; 352: 347-52.
23. Grundtman C, Tham E, Ulfgren AK, Lundberg IE,. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008; 58: 3224-38.
24. Olsen NJ, Park JH,. Inflammatory myopathies: issues in diagnosis and management [review]. Arthritis Care Res 1997; 10: 200-7.
25. Olsen NJ, Park JH,. MRS and NIRS for muscle disease evaluation. Bull Rheum Dis 1995; 44: 4-7.
26. Park JH, Kari S, King LE Jr, Olsen NJ,. Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: dermatomyositis. NMR Biomed 1998; 11: 245-56.
27. Chung YL, Wassif WS, Bell JD, Hurley M, Scott DL,. Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2003; 42: 298-303.
28. Engel AG, Arahata K,. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15.
29. Mantegazza R, Bernasconi P,. Cellular aspects of myositis. Curr Opin Rheumatol 1994; 6: 568-74.
30. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-78.
31. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.